Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

KMT2A::AF6 fusion protein localizes to PML nuclear bodies and undergoes ATO-induced degradation: A potential novel therapeutic approach for KMT2A::AF6-rearranged Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMaddalena BenettonGLGiorgia LongoHHHelmut Hanenberg

Discussion

Loading...

Member takes

Overview

Observational analysis shows ATO reduces KMT2A::AF6 fusion protein in acute myeloid leukemia, suggesting a novel targeted therapy approach.

Key Points

  • KMT2A::AF6 fusion protein undergoes ATO-induced degradation, impacting acute myeloid leukemia pathways.
  • Ubiquitin accumulation in PML nuclear bodies signifies SUMO-dependent proteasomal degradation mechanisms.
  • Analysis revealed that ATO treatment significantly reduced cell viability in acute myeloid leukemia samples.
  • Combination therapies involving Menin inhibitors showed limited efficacy, highlighting a unique target for treatment.

Cite This Study

Benetton et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d348https://doi.org/10.1182/blood-2025-753
View Full Paper
Ask AI
Bookmark
Share